Amgen, headquartered in Thousand Oaks, California, is a biotechnology company employing 26,700 staff, focusing on developing human therapeutics for high unmet medical needs. Its product portfolio includes Aranesp, ENBREL, and Prolia, among others.
AMGN has been in the news recently: On June 6, 2025, Representative Cliff Bentz from Oregon bought Amgen (AMGN) stock valued between $2,002 and $30,000. Despite President Trump's plan to impose 200% tariffs on pharmaceutical imports by August 1, Amgen's stock is expected to benefit from these levies.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
